Search
US$2.4 billion: Eli Lilly Acquires Orna Therapeutics
1 day ago /
Read about 0 minute
Author：小编
Orna Therapeutics' lead candidate, ORN-252, an in vivo CAE-T therapy targeting CD19, is about to enter the clinical stage. Eli Lilly acquired Orna Therapeutics for US$2.4 billion in cash (including upfront and certain clinical milestone payments). Previously, in vivo CAR-T therapies had sparked a wave of mergers and acquisitions at the preclinical stage. In December 2024, AstraZeneca acquired EsoBiotec for US$1 billion; in June 2025, AbbVie acquired Capstan for US$2.1 billion; and in October of the same year, Bristol-Myers Squibb acquired Orbital Therapeutics for US$1.5 billion. These four in vivo CAR-T companies represent different technological approaches.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
